TY - JOUR
T1 - Cetuximab-associated elongation of the eyelashes
T2 - Case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors
AU - Cohen, Philip R.
AU - Escudier, Susan M.
AU - Kurzrock, Razelle
PY - 2011
Y1 - 2011
N2 - Eyelash trichomegaly is an uncommon drug-associated sequelae experienced during treatment with epidermal growth factor receptor (EGFR) inhibitors. Elongation of the eyelashes induced by these agents has predominantly been observed in oncology patients with either colorectal or lung cancer. It is most frequently associated with cetuximab and erlotinib; however, it has also been described in individuals treated with gefitinib or panitumumab. We describe cetuximab-associated eyelash trichomegaly in a woman with metastatic rectal carcinoma. We review the clinical presentation, adverse effects, and management of EGFR inhibitor-related eyelash trichomegaly. The long eyelashes are not a drug-limiting adverse effect and some patients consider the change to be cosmetically enhancing. Trimming the lashes with scissors can usually ameliorate local symptoms. The eyelashes often return to their original length at variable time periods after EGFR inhibitor therapy is discontinued.
AB - Eyelash trichomegaly is an uncommon drug-associated sequelae experienced during treatment with epidermal growth factor receptor (EGFR) inhibitors. Elongation of the eyelashes induced by these agents has predominantly been observed in oncology patients with either colorectal or lung cancer. It is most frequently associated with cetuximab and erlotinib; however, it has also been described in individuals treated with gefitinib or panitumumab. We describe cetuximab-associated eyelash trichomegaly in a woman with metastatic rectal carcinoma. We review the clinical presentation, adverse effects, and management of EGFR inhibitor-related eyelash trichomegaly. The long eyelashes are not a drug-limiting adverse effect and some patients consider the change to be cosmetically enhancing. Trimming the lashes with scissors can usually ameliorate local symptoms. The eyelashes often return to their original length at variable time periods after EGFR inhibitor therapy is discontinued.
KW - Cetuximab, adverse reactions
KW - Epidermal-growth-factor-inhibitors, adverse reactions
KW - Eye
KW - Hypertrichosis, drug-induced
KW - Monoclonal-antibodies, adverse reactions
KW - Trichomegaly, drug-induced
UR - http://www.scopus.com/inward/record.url?scp=78649684719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649684719&partnerID=8YFLogxK
U2 - 10.2165/11531920-000000000-00000
DO - 10.2165/11531920-000000000-00000
M3 - Article
C2 - 20726623
AN - SCOPUS:78649684719
VL - 12
SP - 63
EP - 67
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - 1
ER -